Literature DB >> 25234168

Hes1 suppresses acute myeloid leukemia development through FLT3 repression.

T Kato1, M Sakata-Yanagimoto2, H Nishikii3, M Ueno4, Y Miyake5, Y Yokoyama3, Y Asabe5, Y Kamada5, H Muto2, N Obara2, K Suzukawa3, Y Hasegawa2, I Kitabayashi6, K Uchida7, A Hirao4, H Yagita8, R Kageyama9, S Chiba1.   

Abstract

In leukemogenesis, Notch signaling can be up and downregulated in a context-dependent manner. The transcription factor hairy and enhancer of split-1 (Hes1) is well-characterized as a downstream target of Notch signaling. Hes1 encodes a basic helix-loop-helix-type protein, and represses target gene expression. Here, we report that deletion of the Hes1 gene in mice promotes acute myeloid leukemia (AML) development induced by the MLL-AF9 fusion protein. We then found that Hes1 directly bound to the promoter region of the FMS-like tyrosine kinase 3 (FLT3) gene and downregulated the promoter activity. FLT3 was consequently upregulated in MLL-AF9-expressing immortalized and leukemia cells with a Hes1- or RBPJ-null background. MLL-AF9-expressing Hes1-null AML cells showed enhanced proliferation and ERK phosphorylation following FLT3 ligand stimulation. FLT3 inhibition efficiently abrogated proliferation of MLL-AF9-induced Hes1-null AML cells. Furthermore, an agonistic anti-Notch2 antibody induced apoptosis of MLL-AF9-induced AML cells in a Hes1-wild type but not a Hes1-null background. We also accessed two independent databases containing messenger RNA (mRNA) expression profiles and found that the expression level of FLT3 mRNA was negatively correlated with those of HES1 in patient AML samples. These observations demonstrate that Hes1 mediates tumor suppressive roles of Notch signaling in AML development, probably by downregulating FLT3 expression.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25234168     DOI: 10.1038/leu.2014.281

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  49 in total

1.  Notch-RBP-J signaling is involved in cell fate determination of marginal zone B cells.

Authors:  Kenji Tanigaki; Hua Han; Norio Yamamoto; Kei Tashiro; Masaya Ikegawa; Kazuki Kuroda; Akira Suzuki; Toru Nakano; Tasuku Honjo
Journal:  Nat Immunol       Date:  2002-04-22       Impact factor: 25.606

2.  Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.

Authors:  Andrew P Weng; Adolfo A Ferrando; Woojoong Lee; John P Morris; Lewis B Silverman; Cheryll Sanchez-Irizarry; Stephen C Blacklow; A Thomas Look; Jon C Aster
Journal:  Science       Date:  2004-10-08       Impact factor: 47.728

3.  MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome.

Authors:  Qian-Fei Wang; George Wu; Shuangli Mi; Fuhong He; Jun Wu; Jingfang Dong; Roger T Luo; Ryan Mattison; Joseph J Kaberlein; Shyam Prabhakar; Hongkai Ji; Michael J Thirman
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

4.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.

Authors:  Xose S Puente; Magda Pinyol; Víctor Quesada; Laura Conde; Gonzalo R Ordóñez; Neus Villamor; Georgia Escaramis; Pedro Jares; Sílvia Beà; Marcos González-Díaz; Laia Bassaganyas; Tycho Baumann; Manel Juan; Mónica López-Guerra; Dolors Colomer; José M C Tubío; Cristina López; Alba Navarro; Cristian Tornador; Marta Aymerich; María Rozman; Jesús M Hernández; Diana A Puente; José M P Freije; Gloria Velasco; Ana Gutiérrez-Fernández; Dolors Costa; Anna Carrió; Sara Guijarro; Anna Enjuanes; Lluís Hernández; Jordi Yagüe; Pilar Nicolás; Carlos M Romeo-Casabona; Heinz Himmelbauer; Ester Castillo; Juliane C Dohm; Silvia de Sanjosé; Miguel A Piris; Enrique de Alava; Jesús San Miguel; Romina Royo; Josep L Gelpí; David Torrents; Modesto Orozco; David G Pisano; Alfonso Valencia; Roderic Guigó; Mónica Bayés; Simon Heath; Marta Gut; Peter Klatt; John Marshall; Keiran Raine; Lucy A Stebbings; P Andrew Futreal; Michael R Stratton; Peter J Campbell; Ivo Gut; Armando López-Guillermo; Xavier Estivill; Emili Montserrat; Carlos López-Otín; Elías Campo
Journal:  Nature       Date:  2011-06-05       Impact factor: 49.962

5.  Immunophenotypic features of acute myeloid leukaemia patients exhibiting high FLT3 expression not associated with mutations.

Authors:  Roberta Riccioni; Elvira Pelosi; Viviana Riti; Germana Castelli; Francesco Lo-Coco; Ugo Testa
Journal:  Br J Haematol       Date:  2011-02-20       Impact factor: 6.998

6.  Notch1 functions as a tumor suppressor in mouse skin.

Authors:  Michael Nicolas; Anita Wolfer; Kenneth Raj; J Alain Kummer; Pleasantine Mill; Mascha van Noort; Chi-chung Hui; Hans Clevers; G Paolo Dotto; Freddy Radtke
Journal:  Nat Genet       Date:  2003-02-18       Impact factor: 38.330

7.  Molecular interaction between TLE1 and the carboxyl-terminal domain of HES-1 containing the WRPW motif.

Authors:  D Grbavec; S Stifani
Journal:  Biochem Biophys Res Commun       Date:  1996-06-25       Impact factor: 3.575

8.  Control of the reversibility of cellular quiescence by the transcriptional repressor HES1.

Authors:  Liyun Sang; Hilary A Coller; James M Roberts
Journal:  Science       Date:  2008-08-22       Impact factor: 47.728

9.  Regulation of myeloid leukaemia by the cell-fate determinant Musashi.

Authors:  Takahiro Ito; Hyog Young Kwon; Bryan Zimdahl; Kendra L Congdon; Jordan Blum; William E Lento; Chen Zhao; Anand Lagoo; Gareth Gerrard; Letizia Foroni; John Goldman; Harriet Goh; Soo-Hyun Kim; Dong-Wook Kim; Charles Chuah; Vivian G Oehler; Jerald P Radich; Craig T Jordan; Tannishtha Reya
Journal:  Nature       Date:  2010-07-18       Impact factor: 49.962

10.  Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium.

Authors:  T Ito; N Udaka; T Yazawa; K Okudela; H Hayashi; T Sudo; F Guillemot; R Kageyama; H Kitamura
Journal:  Development       Date:  2000-09       Impact factor: 6.868

View more
  18 in total

1.  Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD+ acute myeloid leukemia.

Authors:  Dan Li; Tongjuan Li; Zhen Shang; Lei Zhao; Qian Xu; Jiaqi Tan; Yun Qin; Yuanyuan Zhang; Yang Cao; Na Wang; Liang Huang; Xiaojian Zhu; Kuangguo Zhou; Liting Chen; Chunrui Li; Ting Xie; Yi Yang; Jue Wang; Jianfeng Zhou
Journal:  Signal Transduct Target Ther       Date:  2020-03-13

Review 2.  Signaling Pathways in Leukemic Stem Cells.

Authors:  Lindsay M Gurska; Kristina Ames; Kira Gritsman
Journal:  Adv Exp Med Biol       Date:  2019       Impact factor: 2.622

Review 3.  Signaling and molecular basis of bone marrow niche angiogenesis in leukemia.

Authors:  R Shirzad; S Shahrabi; A Ahmadzadeh; K R Kampen; M Shahjahani; N Saki
Journal:  Clin Transl Oncol       Date:  2016-01-07       Impact factor: 3.405

4.  MicroRNA-9 promotes proliferation of leukemia cells in adult CD34-positive acute myeloid leukemia with normal karyotype by downregulation of Hes1.

Authors:  Chen Tian; M James You; Yong Yu; Lei Zhu; Guoguang Zheng; Yizhuo Zhang
Journal:  Tumour Biol       Date:  2015-12-17

5.  HES1 is an independent prognostic factor for acute myeloid leukemia.

Authors:  Chen Tian; Yingjun Tang; Tengteng Wang; Yong Yu; Xiaofang Wang; Yafei Wang; Yizhuo Zhang
Journal:  Onco Targets Ther       Date:  2015-04-22       Impact factor: 4.147

6.  Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia.

Authors:  Paul Takam Kamga; Giulio Bassi; Adriana Cassaro; Martina Midolo; Mariano Di Trapani; Alessandro Gatti; Roberta Carusone; Federica Resci; Omar Perbellini; Michele Gottardi; Massimiliano Bonifacio; Armel Hervé Nwabo Kamdje; Achille Ambrosetti; Mauro Krampera
Journal:  Oncotarget       Date:  2016-04-19

7.  Small molecule activation of NOTCH signaling inhibits acute myeloid leukemia.

Authors:  Qi Ye; Jue Jiang; Guanqun Zhan; Wanyao Yan; Liang Huang; Yufeng Hu; Hexiu Su; Qingyi Tong; Ming Yue; Hua Li; Guangmin Yao; Yonghui Zhang; Hudan Liu
Journal:  Sci Rep       Date:  2016-05-23       Impact factor: 4.379

Review 8.  DNMT3A R882 Mutations Predict a Poor Prognosis in AML: A Meta-Analysis From 4474 Patients.

Authors:  Xiao-Qing Yuan; Li Peng; Wen-Jing Zeng; Bin-Yuan Jiang; Guan-Cheng Li; Xiao-Ping Chen
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

9.  Anti-leukemic effects of the V-ATPase inhibitor Archazolid A.

Authors:  Siwei Zhang; Lina S Schneider; Binje Vick; Michaela Grunert; Irmela Jeremias; Dirk Menche; Rolf Müller; Angelika M Vollmar; Johanna Liebl
Journal:  Oncotarget       Date:  2015-12-22

10.  Meis2 as a critical player in MN1-induced leukemia.

Authors:  C K Lai; G L Norddahl; T Maetzig; P Rosten; T Lohr; L Sanchez Milde; N von Krosigk; T R Docking; M Heuser; A Karsan; R K Humphries
Journal:  Blood Cancer J       Date:  2017-09-29       Impact factor: 11.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.